Panel Discussion on.. AI AND ESG: SHAPING THE FUTURE OF SUSTAINABLE GLOBAL SUPPLY CHAINS

11

COMMENTARY ARTICLE

 

AI-driven strategies, which have emerged in diverse high-tech fields over the past few years, are now reshaping supply chains in pharmaceuticals, healthcare, chemicals, and biotechnology by placing sustainability and human well-being at the forefront. Over the course of the early twenty-first century, rapid strides in data-centric technologies and refined metrics for environmental, social, and governance (ESG) considerations have opened up new possibilities for optimizing everything from R&D processes to large-scale manufacturing and global distribution. The pages that follow offer cross-industry perspectives through different panel discussions on how AI and ESG principles are evolving, and how they might define the future of sustainable operations across various sectors.

 

A key advantage of AI-enhanced supply chain management lies in its ability to allocate resources more intelligently while reducing carbon footprints. Many experts agree that intelligent automation can be particularly valuable for navigating complex regulatory frameworks and temperature- or time-sensitive logistics—common challenges in heavily regulated or specialized industries. Traditional methods often struggle with sudden changes, whether they stem from fluctuating market demands or unexpected supply bottlenecks. In contrast, AI-driven platforms can adapt to these fluctuations by deploying predictive analytics and simulation models. This adaptability not only boosts real-time responsiveness but also aligns with ESG targets by minimizing waste, reducing energy consumption, and promoting ethical sourcing strategies.

 

Stakeholders also highlight the economic benefits of introducing AI and ESG considerations at earlier stages in the supply chain. By identifying potential production slowdowns or operational inefficiencies before they escalate, AI-powered solutions help manufacturers and healthcare providers avoid costly emergency measures. Such proactive approaches reduce reliance on less sustainable, short-term fixes, ensuring that both environmental protection and financial stability remain central goals. Moreover, achieving a careful balance of ethical obligations and profit motives simplifies the path to scalability, allowing organizations to rapidly adjust to changing global demands without compromising quality or sustainability targets.

Over the last two decades, a broad spectrum of AI-driven solutions has appeared, catering to laboratories, pilot plants, and full-scale facilities across multiple industries. Many practitioners appreciate the versatility that arises from modular data architectures and flexible analytics platforms, which can be quickly repurposed for different product lines or global markets. Although smaller-scale tools initially received the most attention, the trend is shifting toward large, integrated systems capable of processing massive datasets and seamlessly interfacing with international networks. In some cases—especially with complex or proprietary workflows—fully customized frameworks are developed to address specific ESG mandates and reinforce responsible product stewardship.

 

A more recent development in AI-guided supply chains is the incorporation of process analytical technologies (PAT) and automated decision-making protocols. Panelists noted that AI-driven analytics, when combined with real-time data, can significantly accelerate R&D milestones—ranging from the design of greener packaging solutions to the reduction of harmful byproducts. Once these optimized processes are standardized, basic operational monitoring may suffice to preserve consistent quality. Nevertheless, the dynamic nature of AI allows continuous data streams to yield vital, up-to-date insights, enabling supply chain managers to fine-tune operations to minimize environmental and social impacts. In addition, automated feedback loops are particularly powerful in mitigating out-of-specification outputs by responding quickly to any fluctuations that might compromise safety, quality, or compliance.

 

Despite these advantages, many professionals still question why AI and ESG frameworks are not yet embedded in every aspect of manufacturing and supply chain operations. Their skepticism often reflects the cultural and financial obstacles that arise from longstanding corporate habits and infrastructures. Some experts argue that educational initiatives, beginning as early as undergraduate curricula in life sciences, engineering, and supply chain management, are needed to cultivate a generation of professionals fully conversant in AI-based sustainability methods. Others note that cost barriers, especially for smaller organizations or academic labs, can be substantial. These hurdles, however, may be mitigated by growing awareness that forward-looking companies who invest in ESG and AI not only gain a competitive edge but also secure long-term risk mitigation. Indeed, industry-wide regulations appear to be heading in a direction that favours early adoption of responsible technologies.

 

Classical challenges associated with fragmented data systems and siloed legacy platforms are gradually resolving, thanks in part to the advent of cloud-based architectures capable of handling large and diverse datasets. A renewed focus on data interoperability is making it easier for organizations to adopt a holistic approach, in which information regarding climate impact, resource utilization, and fair labour practices all feed into the same AI-driven analytics engine. Moreover, many software vendors now provide user-friendly interfaces that allow supply chain operators to track ESG goals in real time, bridging the gap between purely algorithmic models and the practical requirements of manufacturing facilities. Looking ahead, it seems likely that AI and ESG considerations will become increasingly intertwined in many regulated industries. Recent global disruptions—most visibly during the COVID-19 pandemic—have underscored both the vulnerabilities in multinational supply chains and the importance of local resilience. These events have spurred renewed emphasis on safe, resource-efficient, and socially responsible operations, including reshoring initiatives in multiple regions.

The potential for automation and advanced analytics to expedite process development is immense, especially when weighed against the pressing need to minimize waste and ensure ethical compliance. In response, emerging guidelines are expected to offer clearer incentives for integrating AI and ESG within supply chains, helping to harmonize global standards on safety, sustainability, and cost-effectiveness. Ultimately, the fusion of AI-driven analytics with ESG objectives signals a transformation in manufacturing and service delivery that goes well beyond incremental improvements. From reducing environmental footprints to ensuring transparent labour practices, and from enhancing patient outcomes to safeguarding community well-being, these emerging strategies mark the start of a promising new era. As data scientists, engineers, healthcare professionals, and policymakers converge, the goal is to forge a supply chain that is not only more efficient and adaptable, but also respects the planet and the people who rely on essential products and services.

 

A total of 19 companies participated in the panel discussions. Their insights—detailing AI and ESG implementation strategies, case studies, and best practices—are featured in the sections that follow this commentary. These contributions provide a wide-ranging view of how organizations are adapting to new AI capabilities and sustainability demands across multiple industries.

 

ANTONIO PESQUEIRA
Researcher, INESC-INOV, ISCTE-IUL – University Institute of Lisbon, Portugal

Antonio Pesqueira is a senior professional in healthcare and pharmaceuticals, focusing on integrating technology to optimize commercial and supply chain processes. He specializes in digital transformation, sales force effectiveness, and data-driven strategies to enhance operational efficiency. Antonio contributes to ISCTE/IUL’s Ph.D. program, researching healthcare data governance and innovation. He has co-chaired the Pharmaceutical Supply Chain & Security World Forum and presented at global industry events. Antonio has published over 20 articles on healthcare digital transformation and agile project management and serves on the editorial board of IJAIMH. He is a certified Scrum Master and IBM Data Scientist.

 

 

–

 

What are the emerging trends in the integration of AI and ESG in global supply chains, particularly in industries like healthcare and pharmaceuticals?

Artificial Intelligence has been used in various forms for many decades but has recently gained attention from a broader audience as it enters mainstream use. In fact, techniques like Multivariate Analysis, Chemometrics, Advanced Process Control, self-optimizing algorithms and real-time optimization could be considered types of AI and already play a role in pharmaceutical manufacturing supply chains. The broad change we are seeing is in interest in AI from a senior level within organizations, who are excited about the potential for algorithmic approaches to improve supply chain performance. This senior support – along with hiring of internal data science teams that understand and can make use of AI-type approaches – has resulted in a real ‘sea-change’ in how supply chains are being managed in leading pharmaceutical companies.

 

Particularly, today we are seeing an accelerating evolution towards advanced levels of digital maturity as pharma companies recognize the need for connected, data-rich manufacturing and supply chains. Specific applications include the areas of advanced scheduling, predictive maintenance and alarm management, delivering advanced asset effectiveness. While these were always priorities, the momentum behind taking an AI approach is accelerating the adoption of these types of solutions with and assigned budgets and teams that understand the tools needed.

 

We also see changes in standards across the industry to systematize the approach towards AI, which is creating a framework for the adoption of these technologies. For example, the second edition of GAMP 5 includes specific consideration of AI/ML and is founded on taking a risk-based approach, including determining the accuracy of training data and clear model validation. This GAMP5 second edition now contains a common regulatory framework for general ML modelling.

 

To enable improved accessibility to medicines, whether that be mass vaccines or personalized medicine approaches, vast quantities of data collection, interpretation and sharing is critical. Real-time data monitoring, modelling and prediction, timely access to process status and the availability of predictive or prescriptive actions underpinned by a real-time, data-driven approach to scheduling are all contributing to an intelligent, smart manufacturing landscape. 

 

What are the most promising AI technologies for enhancing supply chain resilience and agility?

AI technologies that support human decision making are now demonstrating their value, with proactive scheduling being one example. These types of algorithms aim to predict future issues and work around problems before they occur, minimizing the impact of disruptions to supply chains while avoiding excessive safety stocks or other expensive mitigations. AI is particularly promising in this regard since manufacturing and supply chains are becoming increasingly complex. AI tools are allowing supply chain teams to rapidly assimilate and analyze vast quantities of process data – including late-breaking changes to supply and demand or equipment performance – and provide simple and actionable recommendations to users in a timely manner. When we have seen this done effectively, the complexity of the internal solution – including complex extract-transform-load and optimization algorithms – are effectively ‘hidden’ to the end user behind simple user interfaces that feel like a mobile app giving driving directions.

 

One rapid advancement for human augmentation using AI is in alarms and alarm management. The FDA is increasingly focusing on alarm management across pharma operations and is finding significant gaps in how alerts/alarms are handled. By adopting AI/ML into the alarm notification, action and recording process, the ability to detect, record, and triage the alarms is becoming easier to handle. While all alarms are visible to operators, triaging and showing the ‘top’ alarms first is critically important for a timely response that then minimizes product impact to the supply chain.

 

We are also seeing increased adoption of systems such as advanced process control (APC) that take the human out of the loop, autonomously ensuring manufacturing and supply chain resilience. These types of systems interact with low level automation systems and provide robust control in a manner not previously possible. Used together, human-augmented AI along with fully autonomous AI systems can offer powerful solutions to support many manufacturing KPIs.  

 

How do you foresee AI enabling a more circular economy in supply chains by supporting ESG initiatives like waste reduction and resource optimization?

Ideally environmental considerations and resource optimization are built in to process development and subsequent production at the very outset.

Where businesses are striving to improve their ESG credentials there is opportunity to increase the state of digital maturity in a step-by-step fashion, by beginning with a particular process, site, product etc. In these cases, AI can potentially be integrated into the existing operations at various levels and stages.

One area that can be addressed is that of decision latency i.e. the time between an event occurring, accessing the relevant information and being able to implement a data-driven decision. A delayed response to process information could result in batches being discarded unnecessarily, whereas by having access to intelligent, current data a diversion strategy could be invoked thereby minimizing costly wastage and delays in production.  
 
It is tempting to think of resources primarily in terms of equipment and raw materials. When AI is discussed the question of how this impacts a workforce, the human resources, is often raised. It is crucial to recognize how important people are for effective digital transformation.

 

Just as important as the technology itself, the process of change within an organization includes the people. Engaging teams in the adoption of AI techniques can inform changes to the manufacturing process. Whatever the KPIs for digital transformation, for assessing the effectiveness of implementing AI in the process, we have the opportunity to support people in their learning and career development, bring innovation to the industry, which in turn delivers benefits to patients. 
 
As AI/ML is essentially bringing huge sets of data together – sharing inputs/ optimizing outputs, it could be thought of as a digital collaboration – collaboration or working together is a very human trait. 
 
Human intelligence is biological, AI is silicon based – the application of AI on large data sets for the advancement of the pharma/biopharma industry should be a perfect match. 

 

–

 

What are the primary challenges companies face when adopting AI to meet ESG goals, particularly in relation to carbon reduction, ethical sourcing, and transparency?

The key challenges in using AI, regardless of the subject, relate to the availability and quality of the data processed. In other words, is there sufficient data and is it representative and based on the same definitions so that it can be consolidated in a robust and relevant way?

 

Within the partly regulated ESG domain, ensuring consistency is vital, but it is equally important to account for local regulations and contexts. Over-standardized outputs could fail to meet stakeholders’ expectations and end up having a potentially detrimental impact.

 

Finally, any AI deployment must be accompanied by robust change management and skills development to ensure the anticipated ROI while addressing risks related to cybersecurity, intellectual property, data privacy, and ethical practices.

 

What are the key challenges industries face in embedding ESG principles into their global supply chain strategies?

 

Choosing partner companies on ESG criteria requires transparency, change management and adaptability to showcase improved performance or risk management (e.g., compliance).
However, different levels of ESG maturity across businesses, industries, and company sizes pose challenges. Additionally, the absence of harmonized evaluation standards further complicates supply chain dialogue.

In addition, there is an ongoing lack of a strategic and integrated vision for the value that ESG brings to the value chain, caused by the perceived costs of adaptation, limited internal expertise on ESG issues and a focus on short-term priorities. ESG impacts are often only realized over the long term, making it challenging for value chain actors to agree on sharing the short-term costs of implementing necessary actions and adaptations. However, the increasing scope of ESG regulations, such as CSRD, is compelling businesses to formalize their strategies and communicate their performance, resources and ambitions.

 

What role do consumers and stakeholders play in driving ESG compliance in global supply chains, and how should companies respond?

 

An increasing number of global consumers include sustainability issues in their purchase decisions, which is driving demand for transparency in production strategies, ethical practices and corporate reputation. This shift has pushed B2C players to adopt ESG principles and require value chain partners to align with these standards.

 

In addition, the financial sector plays a pivotal role, intensifying efforts to identify ESG risks and prioritizing funding for companies that demonstrate clear commitment and virtuous practices.

 

However, until recently, communication about ESG practices and ambitions of economic players was organized in a non-standardized way, relying on a proliferation of certification labels and individual templates.

 

This is likely to change with the introduction of regulations like the Taxonomy, CSRD and SFRD leading to the emergence of harmonization and standardization of auditable reporting. These frameworks will facilitate objective comparisons, especially among funders.

Given these obligations, all companies in the value chain, whether B2C or B2B, must integrate ESG into their value proposition, with structured communication now serving as a key qualification for business partnerships.

 

How can organizations identify and address data gaps critical to meeting ESG goals through AI?

A successful ESG strategy requires input from different areas of expertise, such as scientific, social, legal, etc, to define ambitions and improvement actions. At this initial stage, AI can support the sharing of best practices across these fields and helps identify innovative solutions.

 

AI can also help companies adapt their strategy to the fast-changing environment of ESG policy, taking into account new regulations and changes to stakeholders’ expectations. It also has a role to play in accelerating the acquisition of key competencies and skills.

 

AI also plays a crucial role in optimizing structured and standardized ESG reporting. It enhances data management and storage, ensures robust and auditable information, validates reporting completeness while identifying data gaps, and can help select the most effective communication and visualization tools. Additionally, AI provides predefined narrative templates, simplifying the creation and management of reports. These capabilities significantly streamline the entire reporting process.

 

Moreover, AI acts as a powerful facilitator and accelerator for ESG initiatives. It helps organizations clearly define key issues and supports the implementation of targeted continuous improvement plans, ensuring progress toward sustainability goals.

 

–

 

 

What are the key challenges industries face in embedding ESG principles into their global supply chain strategies?

Industries today face several significant challenges when it comes to integrating ESG (Environmental, Social, and Governance) principles into their global supply chain strategies. The transition towards more sustainable and socially responsible practices is far from straightforward. This is particularly true in highly regulated sectors like the pharmaceutical industry, where adopting innovative materials and solutions can be quite complex due to stringent regulations.

 

The challenge lies not only in innovating within these constraints but also in navigating the often intricate regulatory landscape. It’s about finding ways to establish institutional dialogues where possible, understanding how to harmonize regulations with the pressing needs of today’s world, and creating a balance between sustainability goals and regulatory compliance.

 

This includes optimizing production processes to reduce waste and increase efficiency, managing supply chains in a way that ensures fair labor practices and reduces environmental impact, and designing packaging that is both functional and environmentally friendly. Innovation plays a crucial role here. It’s not just about developing new drugs and therapies, but also about finding new, more sustainable ways of doing things that can help cut costs, boost efficiency, and ensure wider and fairer access to medicines.

 

Can companies leverage ESG regulations to transform their business models, and if so, how?

Absolutely, companies can and should leverage ESG regulations to transform their business models. At Bormioli Pharma, we’ve made a firm commitment to significantly reducing our environmental impact by setting ambitious targets. By 2030, we aim to cut Carbon Intensity by 30% and Water Withdrawal Intensity by 41%, compared to the 2021 baseline. These goals reflect our recognition of the urgent need to combat climate change and conserve water resources.

 

Our commitment goes beyond mere compliance with regulations. We’re shaking up the recipe for glass production through our ambitious 50-in-5 project. By 2025, we aim to incorporate 50% sustainable materials in our sold products, including a significant increase in glass cullet usage. This isn’t just a target; it’s a commitment to our planet and a testament to our dedication to transforming the industry’s material usage.

 

Furthermore, we’re taking resource management to the next level by setting challenging targets for reducing water withdrawal intensity and carbon intensity. We’re scrutinizing every stage of the product lifecycle, conducting groundbreaking Life Cycle Assessments (LCAs) on glass vials, and gearing up to adopt the Carbon Footprint Systematic Approach (CFSA). This scientific methodology enables us to pinpoint areas for improvement and implement cutting-edge strategies to reduce our carbon footprint.

What role do collaborations and partnerships play in driving sustainability across the biopharma value chain, especially in reducing Scope 3 emissions?

Collaborations and partnerships play an instrumental role in driving sustainability across the biopharma value chain. They enable shared learning, foster innovation, and facilitate the pooling of resources to tackle common challenges. At Bormioli Pharma, we understand the power of collaboration, unleashing innovation through a network of partners made by start-ups, Research Centres, Universities and incubators.

 

To make one single example, we have joined Glass Futures, a globally reaching research initiative focused on sustainable glass production.

 

Glass Futures aims to develop a new approach to glass production that can bring about a technological and economic revolution of great impact to the industry. It’s spearheading research into new low-emission methods and technologies for glass production. Through our collaboration with universities, companies, and research organizations as part of this initiative, we’re helping to bridge the gap between academic studies and commercial implementation. The project plans to launch a unique first pilot furnace, marking a significant step forward in sustainable glass production.

 

What are some successful case studies of implementing green chemistry and eco-design?

One of our most successful case studies is our EcoPositive portfolio. This comprehensive portfolio encompasses over 3,000 glass and plastic packaging solutions and offers a practical and effective path for pharmaceutical companies to transition towards more responsible practices. EcoPositive’s strength lies in its multifaceted approach, which is brought to life through three distinct, concrete pillars: Regenerate, Renew, and Reloop.

 

The Regenerate pillar focuses on maximizing the use of recycled materials. We make bottles from rPET and rHDPE, derived from first-choice waste collection, ensuring high-quality recycled content without compromising safety or performance. By incorporating recycled materials, we reduce reliance on virgin resources and contribute to a circular economy, minimizing waste and maximizing resource utilization.

 

The Renew pillar recognizes the importance of renewable resources. EcoPositive incorporates bioplastics like Green PE, Green PP, and Bio PET 2.0, derived from sustainable sources, further reducing reliance on fossil fuels. This approach aligns with the global shift towards renewable energy and the reduction of fossil-based materials, minimizing the environmental footprint of pharmaceutical packaging.

 

The Reloop pillar emphasizes the use of infinitely reusable materials. Carbon Capture PET bottles are a prime example, showcasing our commitment to circular economy principles and minimizing waste generation. Following the same principle, Advanced rPET bottles are also included in this category, as they are made from the recovery of PET and polyester fiber waste, which are typically difficult to recycle.

 

–

 

 

The ESG Impact of Liquid-Phase Peptide Synthesis (LPPS) on Pharmaceutical Peptide Manufacturing Processes

Peptides are an important modality in the modern pharmacopeia as approved drugs for the treatment of metabolic disorders, cancer, and infectious diseases. However, traditional peptide synthesis methods, especially solid-phase peptide synthesis (SPPS), present challenges in meeting environmental, social, and governance (ESG) goals due to their substantial resource consumption and environmental impact. The need for sustainable methods of peptide synthesis is particularly acute given the success of peptides for the treatment of diabetes and obesity; diseases that affect a large percentage of the population. As a result, the demand for synthetic peptides is larger than it has ever been in the past. Liquid-phase peptide synthesis (LPPS) offers a promising alternative with significant ESG benefits, creating opportunities for a more sustainable pharmaceutical industry.

 

Environmental Benefits of LPPS

One of the most critical environmental challenges in peptide manufacturing is the extensive use of solvents and reagents, particularly in SPPS. These materials contribute significantly to the process’s environmental footprint, generating hazardous waste that requires energy-intensive disposal methods. LPPS addresses this issue by utilizing more scalable and resource-efficient processes. LPPS requires fewer solvent exchanges compared to SPPS, reducing solvent consumption per unit of peptide produced. Additionally, the potential to integrate solvent recovery systems in LPPS can enhance waste reduction, aligning with circular economy principles. By minimizing solvent waste, LPPS supports pharmaceutical companies in meeting stringent environmental regulations and reducing costs associated with hazardous waste disposal.

 

Process Mass Intensity (PMI) is a useful metric for evaluating the sustainability of chemical processes, representing the ratio of material input to the final product output. LPPS processes inherently achieve lower PMI compared to SPPS because of the lower demand for solvent and more efficient use of reagents and reactants. Linear synthesis of peptides on solid phase typically relies on solvent intensive chromatographic purification to achieve pharmaceutical quality peptides. Leveraging convergent synthetic routes to peptides can provide significant improvements in the control of product quality throughout the process such that the reliance on chromatography to purify can be made much more efficient, if not eliminated entirely.

 

LPPS aligns with green chemistry principles by enabling the use of less hazardous solvents, reducing the inputs into the process. LPPS is able to use eco-friendly solvents like 2-methyltetrahydrofuran to replace large volumes of N,N-dimethylformamide further reduce environmental harm, paving the way for greener peptide manufacturing.

 

Social Impact of LPPS

The reduced use of toxic solvents and significantly reduced solvent volumes makes for safer operating conditions associated with LPPS processes which have a direct positive impact on worker safety. Traditional SPPS methods often involve handling large quantities of hazardous solvents, posing risks of exposure to toxic fumes and chemical spills. LPPS reduces these risks by limiting the volume and frequency of solvent use, thereby creating a safer workplace environment.

 

Perhaps most importantly, LPPS reduces the cost and complexity of peptide synthesis, making the manufacturing of peptides more affordable. This cost reduction can translate to lower prices for peptide-based drugs, improving access to these essential medicines. Expanding access to life-saving treatments aligns with the social goals of ESG frameworks, promoting equity in healthcare.

 

LPPS’s ability to reduce environmental harm and enhance sustainability can improve the public perception of pharmaceutical companies. Engaging communities and stakeholders with transparent data on the environmental and social benefits of LPPS helps build trust and strengthens corporate social responsibility initiatives.

 

Governance Implications of LPPS

Regulatory bodies increasingly emphasize sustainability in manufacturing processes. Frameworks like the Global Reporting Initiative (GRI), Sustainability Accounting Standards Board (SASB), and Corporate Sustainability Reporting Directive (CSRD) require organizations to disclose their environmental impact, including resource use and waste management. LPPS enables pharmaceutical companies to comply with these frameworks more effectively by reducing solvent consumption and hazardous waste generation.

 

Furthermore, GMP regulations are evolving to encourage greener manufacturing practices. LPPS’s compatibility with these emerging guidelines positions companies for long-term compliance and reduced regulatory risk.

 

Governance frameworks emphasize the importance of traceability in supply chains to ensure ethical sourcing and compliance with ESG goals. LPPS processes can integrate AI-driven monitoring systems to track solvent use, energy consumption, and waste generation in real-time. This level of transparency helps companies maintain accountability and improve governance practices.

 

Dependence on traditional SPPS methods exposes companies to risks associated with volatile raw material prices, regulatory non-compliance, and reputational damage from unsustainable practices. By adopting LPPS, companies can mitigate these risks and demonstrate a proactive approach to sustainability, enhancing investor confidence and long-term business resilience.

 

Challenges and Opportunities in Scaling LPPS for ESG Impact

Transitioning from SPPS to LPPS may require upfront investment in process development and optimization. However, the long-term cost savings from reduced resource consumption and waste disposal make LPPS a financially viable option. Collaboration with industry partners and government incentives can offset initial costs and accelerate adoption.

 

Implementing LPPS requires skilled personnel to manage and optimize the processes. Pharmaceutical companies and drug manufacturers must invest in training programs to equip their workforce with the necessary expertise, ensuring a smooth transition to LPPS. These programs can include AI-powered modeling and optimization to identify sustainability practices and deliver efficient processes.

 

Partnerships between pharmaceutical companies, academic institutions, and manufacturing partners can drive innovation in LPPS. Shared resources and knowledge can accelerate the development of sustainable peptide synthesis methods, benefiting the entire industry.

 

Integrating AI technologies into LPPS processes can further enhance efficiency and sustainability. Predictive models can optimize reaction conditions, monitor resource consumption in real-time, and identify opportunities for improvement, aligning with ESG goals of waste reduction and resource optimization. The adoption of LPPS supports circular economy initiatives by promoting solvent recovery and reuse. Expanding these principles across the peptide manufacturing supply chain can drive further reductions in resource use and environmental impact. Pharmaceutical companies using LPPS can collaborate with regulators to advocate for policies that incentivize sustainable practices, such as tax benefits for implementing green chemistry methods or funding for R&D in sustainable manufacturing.

 

Conclusion

Liquid-phase peptide synthesis represents a transformative opportunity for the pharmaceutical industry to align with ESG goals while maintaining high standards of product quality and efficiency in the delivery of life-saving medicines. By reducing solvent usage, improving safety, and enhancing compliance with sustainability frameworks, LPPS supports a more environmentally and socially responsible approach to peptide manufacturing.

 

–

 

 

What future regulations or industry standards do you anticipate will have the most significant impact on the adoption of AI in ESG practices?
As energy costs continue to rise and environmental regulations become more stringent, effective energy management is increasingly important for companies looking to be more sustainable and remain competitive in the global market.

 

The foundation for any energy management and carbon reduction strategy is the implementation of an energy data management system. Energy data management systems are designed to address challenges of decarbonization through the supervision of renewable energy generation, energy management, and the monitoring of utilities and building automation.

 

Here, the ISO 50001 standard is preeminent. It provides a robust framework for energy management in the industrial sector, offering a pathway to improved energy performance, cost savings, and environmental sustainability. We see a growing role for AI in these applications. AI can offer predictions, modelling and insights to enhance continuous improvement decisions and strengthen ISO 50001 energy management systems.

 

ISO 50001 uses the familiar Plan-Do-Check-Act (PDCA) cycle, which is used in other management system standards, including ISO 9001 (quality management systems) and ISO 14001 (environmental management systems).

 

• The Planning phase of an ISO 50001 system involves understanding the current energy situation of the organization. It includes setting goals and creating improvement plans based on Energy Performance Indicators (EnPIs). These indicators are crucial for measuring and tracking energy performance over time.
• The Do phase is about putting the plans into action. It involves implementing energy management measures, training staff, and making the necessary changes to processes and equipment to improve energy efficiency.
• In the Check phase, the results of the implemented actions are measured, monitored, documented, and evaluated. This step is critical for understanding the effectiveness of the energy management measures taken. It is then possible to prioritize actions for further improvement.
• Based on these findings, positive experiences and continuing development across the entire organizational system and various production teams should be reinforced during the Act phase. It’s about taking corrective actions where needed and setting new goals for the next cycle.
• By following the PDCA cycle and engaging all levels of the organization, companies can systematically approach energy management, leading to long-term benefits.

It’s likely data interpretation and analysis will become more important as quick wins are achieved and improvement becomes more difficult. Here, AI can support ISO 50001 initiatives by training predictive models, modelling scenarios, predicting likely impacts of different scenarios to intelligently prioritize actions and also to predict future conditions. AI data governance regulations will have far less relevance here than any potential future regulations or standards around responsible AI use.

Further, future environmental regulations may drive increasing adoption of sophisticated AI-powered analytics and predictive capabilities in energy data management systems so that organizations are better placed to meet more stringent ESG targets.

 

What are some successful case studies of implementing green chemistry and eco-design?

One of the most successful impacts that we’ve seen in green chemistry and eco-design is the transition to modular production in process development and manufacturing.

 

In life sciences industry, the established conventional architecture of multi-product plants is frequently inefficient. They are designed to be used in a variety of ways without the need for time-consuming set-up or adjustment work when changing products (except for cleaning). However, the most suitable technology is rarely used because the plant hasn’t been designed for a specific product.

 

Today, we are seeing a transition from traditional multi-product plants to modular design. Reductions in carbon emissions of around 30% are achievable and have been documented in the Federal Energy Research Report 2021.

 

Our customer, a big player in life sciences, has made significant progress in sustainability and operational efficiency through its implementation of Modular Plant design according to the Module Type Package (MTP) standard. In addition to the 30% reduction in carbon footprint, it achieved a 15% decrease in cost of goods sold (COGS).

 

With the modular plants concept, the exchange of functional units – process equipment assemblies (PEA) – is assured by modular automation with the common standard of Module Type Package NAMUR/VDI/VDE 2658.

 

Our customer’s 30% carbon reduction is based on a comparison between the process running in production on universal lines vs. modular lines. New technologies were used, including thin film and short path evaporators as well as membrane plants and alternative extraction and crystallisation technologies.

 

In the future, redesign and updates will be more affordable. After all, the redesign of an entire line will not be required, only individual modules.

The achieved 15% reduction in COGS is closely linked to the same modular principles. By using equipment designed for specific production needs, the company achieves higher productivity and lower operational costs.

The new, modular approach also supports a “scale-out” strategy, enabling gradual expansion as market demand increases, reducing the risk associated with large-scale investments.

 

We can see that the benefits of eco-design go beyond environmental performance. They include:

 

• Flexibility: Easy exchange of functional units for different products.
• Optimization: Focused design enhances technology integration.
• Scalability: Gradual growth reduces financial risks.
• Global distribution: Production closer to customers improves logistics.
• Resource efficiency: Higher yields and reduced waste.
• Reduced working capital: Lower inventory levels optimize capital management.

 

Our customer plans to launch additional modular infrastructures in future, further solidifying its commitment to efficient and sustainable manufacturing practices. Through MTP technology, it has reduced emissions and costs and set a benchmark for innovation in the pharmaceutical industry.

 

What immediate steps can companies take to source and standardize ESG data for AI-driven supply chain initiatives, particularly in fragmented industries like fine and specialty chemicals?

 

The old data science maxim of “garbage in, garbage out” is especially relevant in AI applications.

An accurate, unified data foundation is essential for comprehensive AI-driven analysis.

 

Yet, one of the primary challenges in industrial settings – particularly in fragmented industries like fine and specialty chemicals – remains the diversity of equipment and systems, each generating data in different formats. Data collected from this heterogeneous industrial equipment must be standardized and homogenized if it is to be used to deliver meaningful analyses and insights.

 

By transforming disparate data streams into a cohesive dataset, AI applications can deliver more accurate insights and predictive capabilities across the entire production ecosystem. In the context of supply chain ESG initiatives, an Energy Data Management System (EDMS) according to ISO 50001 is the obvious home for such a dataset.

 

To ensure that the EDMS does not suffer from “garbage in” syndrome, firms should invest in a number of capabilities to source and standardize ESG data for their AI-driven supply chain initiatives:

 

• Extended system communication. It is essential to connect the various elements of industrial systems, from the shop floor to higher-level management systems. Sensors and IoT devices can be deployed throughout the supply chain to collect real-time data.
• Versatile connectivity. A data platform that can interface with a wide range of equipment and systems facilitates comprehensive and standardized data collection.
• Data contextualization. In the pharmaceutical industry, contextualization and aggregation offers more connections between data and real processes. Clear metrics and KPIs should be defined.
• Real-time awareness. Real-time monitoring and control are crucial for maintaining up-to-date data and enabling swift action. Real-time monitoring of ESG-related parameters throughout the supply chain is possible using industrial automation software systems. Robust and highly available systems that comply with relevant standards offer additional benefits: users can set up alerts and notifications about deviations from ESG targets or compliance requirements.
• Data storage. To prepare for AI-driven initiatives, there should be an established centralized data platform. A robust and reliable EDMS solution that provides comprehensive data management is essential for handling large volumes of data.
• Integration with AI applications. Data should be stored in a format that is easily accessible for analysis and reporting, e.g., by standard IT interfaces like REST API, GraphQL and Python. This way, firms can integrate their collected ESG data with AI applications for predictive analytics and decision-making support.

 

By taking these steps and leveraging the capabilities of powerful software solutions for industrial control, companies in the life sciences industry can create a solid foundation for AI-driven ESG and supply chain initiatives.

 

The foundation of sufficient, valid, and comprehensive data enables organizations to train external or custom algorithms and set up predictive models, enhancing decision-making processes. More accurate forecasting, anomaly detection, and process optimization are possible. Plus, as the quality and quantity of data improves, so does the accuracy and reliability of these predictive models, leading to more informed strategic decisions.

 

–

 

 

What are the emerging trends in the integration of AI and ESG in global supply chains, particularly in industries like healthcare and pharmaceuticals?

The implementation of AI tools in the pharma supply chains works with different speeds. The pharmaceutical industry is one of the most regulated fields and regulations are increasing. Therefore, we can classify these levels for AI implementation:

 

Advanced:

• Molecular and Drug Design
• Simulation of Processes, it seems, bioprocesses are more advanced.
• Data analysis and processing
• Warehousing and storage: larger companies more advanced than small and mid-sized

Partially implemented:

• Analytical and Quality Control (planning, datalogging, data evaluation)
• Logistics and transportation
• Process automation, continuous processes are more advanced

Implementation still individual:
Chemical production in pharma chem (still mostly based on batch operations and sometimes manual control)

 

In general, most small and mid-sized companies show a lower level of AI use than larger groups which can afford to dedicated resources and funding and people.

 

What are the primary challenges companies face when adopting AI to meet ESG goals, particularly in relation to carbon reduction, ethical sourcing, and transparency?

 

High regulation level of the pharmaceutical industry, process change, process validation, to take customers on board for changes.

 

Funding for small and mid-sized companies.

 

How can AI help address regulatory challenges surrounding ESG compliance, especially with evolving frameworks like GRI, SASB, and CSRD?

The harmonization of national and international rules and regulations for ESG compliance. Also, in other regulatory and compliance fields we have leader regulations such as the US FDA to which most providers have to comply with if they want to work with US customers.

 

In particular the harmonization between the big player countries USA, India, China, Japan and the EU, in a difficult global political situation.

In what ways do you foresee AI transforming future ESG practices across industries, and how should companies prepare for these advancements?

Each company should define the most suitable way to start with, using pilot projects to get acquainted to AI and build internal know-how.

 

For manufacturers, analytical and quality control may be a good entry point, for larger groups warehousing and logistics as well.

 

In the meantime, for process design and route scouting AI tools are available, but still need the human cross-checking. AI tools are not yet able to replace human thinking and reasoning, the latter is also based on intuition and creativity, manual experience in the lab, experience which is difficult to transmit to AI algorithms.

 

In fact, an AI algorithm does not know what it is doing, it is executing commands although at a very sophisticated level. For example, the first computer that beat a human chess player for the first time, did not know what it was doing, but calculated huge numbers of possible moves that were fed into the system before.

 

Therefore, AI tools can work well in a well-defined environment, but cannot yet compete with humans when the context is not well defined and surprises or exceptional situation arise which are not foreseen in the algorithms.

 

What new skills and capabilities will employees need to effectively leverage AI for enhancing ESG initiatives within organizations?

Using and learning to apply AI is a new profession, and dedicated teams should be formed within a company to generate know-how and experience which then will first be applied in trials, pilot projects and with lead customers. This means, companies should work according to the principles of Innovation Management.

 

How do you see AI improving transparency and traceability in ESG-related activities, particularly in ensuring ethical sourcing and compliance with labor standards?

Transparency goes into conflict with IP and confidential know-how. Therefore, the application of AI in the industry should be done with external, specialized providers able to apply the systems to the individual needs for a company, following international rules and standards.
AI tools can support patent search and evaluation as an example.

 

What future regulations or industry standards do you anticipate will have the most significant impact on the adoption of AI in ESG practices?

The usual suspects: US FDA, EMA, Environmental Organizations and more.

 

What are the most promising AI technologies for enhancing supply chain resilience and agility?

The main objective should be to maintain the availability of critical and life saving drugs even during supply chain interruptions or problems. Apart from re-shoring production, this can be done by smart inventory management, fed by logistics and supply chain management from different sources, i.e. not to depend on single sources. Customers should take the lead and set the standards, similar to quality, environmental and regulatory compliance and sustainability standards.

 

How can AI be used to predict and mitigate supply chain disruptions, such as those caused by global events or regulatory changes?

• Scenario exercises and real-time inventory and supply management
• Some global events cannot be predicted or anticipated (see Covid-19, military conflicts or natural catastrophes (earthquakes, wildfires, floodings etc.).

 

What are the key challenges industries face in embedding ESG principles into their global supply chain strategies?

• Available resources for small and mid-sized companies;
• Understanding and sponsoring by the top management;
• Available computing power to run AI algorithms and their vulnerability in case of power failures and other impacts;

 

What role do consumers and stakeholders play in driving ESG compliance in global supply chains, and how should companies respond?

The context needs to be created by governments and international authorities, followed by end customers setting standards, like actual regulatory and compliance standards.

 

What are the potential risks of relying on AI to meet ESG goals, and how can companies mitigate them?

• AI systems rely on continuous power supply; this is the reason why Meta for example is already planning to have its own nuclear power plants;
• Therefore, available energy sources are the most basic and crucial factor to keep AI systems going.
• Still, the servers running AI applications consume huge amounts of energy, with the growing use of AI, energy optimization needs to be tackled now, again using AI;

 

How do you foresee AI enabling a more circular economy in supply chains by supporting ESG initiatives like waste reduction and resource optimization?

AI tools can help to recycle materials, lower raw material, solvent and other materials consumptions, help to choose the most efficient and lower environmental impact for sea transportation (still the most important transportation ways for drugs, raw and starting materials and intermediates).

 

Can companies leverage ESG regulations to transform their business models, and if so, how?

Today it is premature, the providers landscape is highly differentiated varying from very small to global players. Affordable AI tools will be crucial to apply the systems industry wide and globally.

 

What role do collaborations and partnerships play in driving sustainability across the biopharma value chain, especially in reducing Scope 3 emissions?

The role of a government is to create the economic, legal, infrastructural and organizational context for companies to operate in a secure and reliable way. For the citizen this means the availability of drugs and in particular essential and life saving drugs. Today, most governments’ focus is on lowering drug prices to contain health spending. This was one of the main reasons why the drug supply chain has moved to mainly China and India for raw materials, mature APIs and drugs. Example: In Europe, there are only a few antibiotic manufacturing sites left (one is Sandoz, Kundl, Austria) because the pharma industry was not interested in further develop new antibiotics and to manufacture and sell low-cost antibiotics. This led to a continuing shortage of important antibiotics in Europe. Moreover, antibiotic resistant strains have evolved, and no or only a few efficient new antibiotics are on the market. The governments should therefore incentivate the production of essential drugs at least in Europe while continuing to also source in Asia.

 

What immediate steps can companies take to source and standardize ESG data for AI-driven supply chain initiatives, particularly in fragmented industries like fine and specialty chemicals? 

• Forming teams or task forces to get introduced into AI and ESG;
• Shaping first pilot projects to generate understanding and know-how;
• Participating in national and international associations and organizations to foster ESG;
• Start working with specialized providers to acquire know-how;

 

How can organizations identify and address data gaps critical to meeting ESG goals through AI?

Working with specialized providers, for example in process development and simulation with companies like Data-How, Switzerland and others.

 

What strategies can smaller companies adopt to avoid misinterpretations or biases in early-stage AI-driven ESG metrics? 

Start working with external consultants and form an internal ESG and AI team.

 

What role do industry partnerships play in helping smaller companies participate in AI-driven ESG pilot programs? 

Could be done within existing industry associations such as Aschimfarma, CPA, EFCG and others. Small companies often do not have the resources to build teams.

 

Which foundational ESG metrics should companies prioritize to support scalable AI integration in supply chains? 

Today, there are already enough papers and publications about ESG key metrics such as:
Environmental: CO2 and other green-house gases emissions, energy consumption, energy sources, water consumption, waste management;

Social: Work practices and ethics in Supply Chain Management, Codes of Conduct; diversity at work, sustainability of the supply chain, CSR activities

Governance Metrics: Diversity in the BoD and Top Management, Compensations, Enterprise Ethics and Codes of Conduct, Compliance and Risk Management.

 

–

 

AI and ESG in Pharma and Biotech: Navigating the Intersection for a Sustainable Future

The pharmaceutical and biotech sectors are at a pivotal moment where integrating Artificial Intelligence (AI) and Environmental, Social, and Governance (ESG) initiatives is no longer optional but necessary. As global supply chains grow increasingly complex, stakeholders—from consumers to investors—demand transparency, ethical practices, and sustainability. In parallel, AI is being celebrated as a transformative tool to achieve these goals. But how do these forces converge, and what challenges and opportunities do they present for the pharmaceutical and biotech industries?

 

Consumers and Stakeholders: The ESG Catalysts

ESG compliance has moved beyond regulatory requirements to become a strategic differentiator in the pharma and biotech industries. Consumers are more health-conscious and sustainability-driven, while investors are tying capital allocation to ESG performance metrics. This dual pressure is reshaping how companies approach their supply chains.

 

Take the case of raw material sourcing for Active Pharmaceutical Ingredients (APIs). Consumers increasingly demand assurance that these materials are sourced sustainably and ethically, especially from regions with weaker environmental regulations. For instance, sourcing palm oil derivatives—a critical excipient in many formulations—has faced scrutiny due to its ecological impact. Companies like Johnson & Johnson have responded by publicly committing to sustainable sourcing certifications, ensuring alignment with consumer and stakeholder expectations. Pharma and biotech companies must embrace transparency through digital tools. AI-powered blockchain solutions, for example, can provide traceability across supply chains, enabling companies to demonstrate compliance with ESG standards. Additionally, fostering supplier collaborations for ESG audits can ensure ethical practices across the value chain.

 

Risks of Relying on AI for ESG Goals

AI’s role in driving ESG goals cannot be overstated, but the risks associated with its adoption are equally significant. In the pharma space, one key challenge is data bias. For example, AI algorithms designed to optimize clinical trial site selection may inadvertently exclude underrepresented populations due to historically skewed datasets. This undermines the “Social” aspect of ESG by perpetuating health inequities. Another concern is AI’s environmental impact.
Large-scale AI models require immense computational resources, leading to substantial energy consumption. The paradox of adopting energy-intensive AI tools is a critical consideration for a sector aiming to reduce its carbon footprint. Companies should prioritize diverse and representative datasets during model training to address bias. Collaborating with regulatory bodies and academic institutions can help ensure inclusivity in AI-driven decisions. Additionally, green AI practices—such as using energy-efficient cloud platforms or optimizing AI algorithms for lower power consumption—can align AI adoption with environmental goals.

 

Enabling a Circular Economy in Pharma Through AI

The circular economy—a model focused on minimizing waste and maximizing resource efficiency—is gaining traction in the pharmaceutical and biotech sectors. AI is a game-changer in this space by enabling innovative waste reduction and resource optimization approaches. One example is managing solvent use during chemical synthesis. AI-powered predictive analytics can optimize solvent selection and recycling, significantly reducing hazardous waste. This aligns directly with the “Environmental” pillar of ESG. Companies like GSK leverage AI to improve API production process efficiencies, reducing waste and energy consumption.

 

Similarly, AI is enabling advanced product lifecycle management for drug delivery systems. For instance, in developing pre-filled syringes and inhalers, AI can identify design modifications that make these products more accessible to recycle, thus closing the loop in product usage. AI’s role in enabling a circular economy will grow as pharma companies embrace waste valorization strategies, such as converting by-products from chemical synthesis into reusable raw materials. These innovations drive sustainability and offer cost-saving opportunities, making them a win-win for ESG compliance and profitability.

 

AI and ESG in Biopharma: Lessons from COVID-19

The COVID-19 pandemic showcased the biopharma industry’s ability to adapt and innovate under immense pressure, with AI playing a crucial role. From accelerated vaccine development to efficient supply chain management, the pandemic provided a blueprint for integrating AI and ESG goals. Consider Moderna and Pfizer-BioNTech’s rapid development of mRNA vaccines. AI-driven algorithms helped optimize protein structure predictions, speeding up the discovery and development phases. Beyond innovation, these efforts aligned with ESG goals by prioritizing global health outcomes—a key “Social” metric.

 

AI was instrumental in ensuring equitable vaccine distribution on the supply chain front. By analyzing population density, infection rates, and logistical constraints, AI tools enabled the delivery of vaccines to underserved regions, addressing disparities in healthcare access. Despite these successes, the industry has room to grow in integrating ESG principles more holistically. For example, AI can be further leveraged to monitor carbon emissions across supply chains or to optimize the sourcing of critical raw materials like lipids used in mRNA vaccines. By investing in AI systems tailored for ESG metrics, biopharma companies can build on the lessons of COVID-19 to drive long-term sustainability.

 

Practical Pathways for AI and ESG Integration

The pharma and biotech industries need a comprehensive and strategic approach to integrate AI with ESG principles effectively. First, companies should focus on implementing explainable, transparent, and interpretable AI systems that foster trust among stakeholders. These systems should demonstrate how AI-driven decisions support ESG objectives, such as improving supply chain visibility or ensuring inclusivity in clinical trials.

 

Collaboration across ecosystems is another critical element, as achieving ESG compliance cannot be done in isolation. Partnering with suppliers, regulators, and academic institutions can help create a unified framework where AI tools are seamlessly aligned with sustainability goals.
Establishing clear, measurable ESG metrics is also essential. For instance, companies might aim to cut carbon emissions by a specific percentage or achieve entirely ethical sourcing by a set deadline. AI can be leveraged to monitor and report progress, ensuring these objectives remain on track.

 

Finally, prioritizing education and training is vital to successful implementation. Teams must be equipped with a thorough understanding of AI technologies and ESG principles. Investing in workforce development ensures alignment across all functions and strengthens the integration of AI into sustainability strategies.

 

While challenging, the integration of AI and ESG in pharma and biotech presents an unparalleled opportunity to drive sustainability, foster trust, and address societal needs, ultimately positioning these sectors as pioneers in shaping a sustainable and equitable future through responsible innovation.

 

–

 

 

AI Meets ESG: Redefining the Future of Global Supply Chains

Picture this: A pharmaceutical executive sits in her office, contemplating the twin transformations reshaping her industry. AI promises unprecedented supply chain visibility, yet its energy and resource footprint raises eyebrows. ESG principles lead to broader value creation (1), but implementation challenges abound. Welcome to the new reality of global supply chains.

 

The sustainability imperative in supply chains has evolved from a “nice-to-have” to a “must-have.” Yet, the complexity of global supply networks makes this transformation anything but straightforward. Let’s explore how AI and ESG is reshaping this landscape.

 

AI: Partner with a Price Tag

One truth becomes increasingly clear as we work with boards and executives: AI is a powerful collaborative enabler, but like any partnership, it comes with costs. While AI’s ability to analyze, model, and assess across supply chain entities offers compelling advantages, we must acknowledge its energy and resource consumption footprint.

Consider how AI is reshaping traditional business models. As transparency increases through AI-powered analytics, previously differentiated strengths might become standardized—turning unique value propositions into vanilla offerings. The question for leaders becomes: How do we harness AI’s capabilities while maintaining distinctive value? ESG is one such tool.

 

Consider how Unilever deployed machine learning algorithms to analyze their palm oil supply chain originating in Malaysia and Indonesia. The system processes satellite imagery, supplier data, and local reports to identify potential sustainability risks in real-time. This initiative has helped them achieve 97.1% traceability for their deforestation-free palm oil supply chain (2)—a feat unimaginable just a few years ago.

 

The Regulatory Wave

Major economic regions in the EU, Asia and the Americas are driving business model transformation through heightened regulation. This isn’t just about carbon emissions anymore. It’s about recognizing externalities across the full spectrum: biodiversity, water, waste, social impacts within organizations and communities, and governance structures.

 

This brings us to a crucial point: governance clarity around AI delegation. What decision rules and values do we embed? What quality assurance measures do we implement? As accountable decision-makers, these choices shape not just compliance but competitive advantage.

AI-powered blockchain solutions are emerging as the answer. Take Walmart’s food traceability initiative, which can trace the journey of mangoes from farm to store in 2.2 seconds—a process that previously took seven days (3). This level of transparency isn’t just about compliance; it’s about building trust with increasingly conscious consumers.

 

Beyond Compliance: The Four Profiles of Transformation

In Greensight, the Sustainability Guide for Company Directors four distinct profiles are identified in the sustainability journey (4):

1. The Observer: Watching from the sidelines, a rational choice only if there’s minimal pressure on their business model
2. The Pledger: Strong on statements, weak on action
3. The Complier: Investing in necessary changes to address regulatory needs
4. The Transformer: Seeing brand and market opportunities, investing in business model innovation

 

Here’s the reality: Observers and Pledgers face existential risks as access to funding, markets, and customers evolves. Compliers might stay in the game, but compliance alone isn’t a competitive advantage. The future belongs to Transformers who see beyond immediate returns.

 

Challenges and Opportunities in Action

The pharmaceutical and chemical industries face unique challenges in embedding ESG principles:

• Navigating differing local cultural, commercial, and competitive priorities
• Moving beyond short-term cash optimization to multi-stakeholder value creation
• Overcoming the outdated perception of ESG as a cost rather than a value creator

 

Yet, we’re approaching an inflection point similar to the Kaizen driven Total Quality Management revolution some years ago in Japan. Just as that movement proved high quality was possible at reasonable prices, ESG principles are demonstrating that sustainable products can be both high-quality and commercially valuable.

 

The Collaborative Future

The most exciting developments lie in collaboration across value chains. Take the biopharma sector: moving beyond Scope 3 emissions into multi-element impact optimization reveals untapped value in waste reduction, health impact improvements, and innovative commercial models.

 

L’Oréal’s AI-powered sustainable product formulation system is a prime example (5). The system analyzes thousands of ingredients against ESG criteria, helping create products that meet both sustainability goals and consumer demands. This isn’t just compliance; it’s innovation driven by ESG principles. It’s delivered by value chain collaboration.

 

These collaborations, powered by AI but guided by ESG principles, create more durable commercial outcomes and sustainable results. They represent a fundamental shift in how we view value creation—extending horizons from quarterly results to generational impact.

 

The Path Forward

For boards and executives, the message is clear: The twin forces of AI and ESG are reshaping global supply chains. Success lies not in choosing between them but in harnessing their synergies while managing their tensions.

 

The future belongs to organizations that can leverage AI’s analytical power while embedding ESG principles into their core strategy. This isn’t about perfect solutions—it’s about progress toward more sustainable, transparent, and valuable supply chains.

 

Remember, in this AI+ESG transformation, standing still is moving backward. The question isn’t whether to embrace these changes, but how quickly you can turn them into competitive advantage.

 

References and notes

1. “83 percent of C-suite leaders and investment professionals say they expect that ESG programs will contribute more shareholder value in five years than today. They also indicate that they would be willing to pay about a 10 percent median premium to acquire a company with a positive record for ESG issues over one with a negative record. That’s true even of executives who say ESG programs have no effect on shareholder value.” https://www.mckinsey.com/capabilities/sustainability/our-insights/the-esg-premium-new-perspectives-on-value-and-performance Feb 2020
2. https://www.unilever.com/sustainability/nature/sustainable-palm-oil/
3. https://www.researchgate.net/publication/326188675_Food_Traceability_on_Blockchain_Walmart’s_Pork_and_Mango_Pilots_with_IBM
4. “Greensight: The Sustainability Guide for Company Directors” (Flinn, J., 2022) https://www.amazon.com.au/Greensight-Sustainability-Guide-Company-Directors/dp/0994323379
   L’Oréal is aiming to make 95% of ingredients in its formulas bio-based, derived from abundant materials or from circular processes by 2030. https://sustainabilitymag.com/articles/how-loreal-is-using-biotech-for-sustainable-beauty Sept 24 2024

–

 

 

ESG & Innovation: Driving Sustainable Progress in R&D

As we start 2025, the intersection of Environmental, Social, and Governance (ESG) principles with innovation has never been more critical. Our company has been at the forefront of integrating ESG into our research and development (R&D) processes, setting ambitious goals and pioneering new methodologies to ensure sustainable progress. This article outlines our journey, key initiatives, and the impact of our efforts on the broader industry.

 

Historical Context and Baseline Establishment

In 2024, we laid the groundwork for our ESG efforts, embedding these principles within our R&D framework. A significant milestone was achieved with the European Commission’s official notification regarding our French IPCEI (Important Project of Common European Interest) program. This program addresses the demand for critical medicines, such as macrolide antibiotics and corticosteroids, incorporating disruptive environmental innovations and strong ESG and HSE components. The recognition by the European Commission will help us carry out innovative projects that are key to long-term European sovereignty and which will contribute to the green transition of the pharmaceutical industry. In short, the launch of IPCEI marked a turning point, placing ESG at the heart of our “Greening processes” and catalyzing our transformation.

 

The initial phase involved establishing a baseline for our ESG efforts. This was a crucial step, as it provided a clear starting point from which we could measure progress. At this stage, we conducted a comprehensive review of our existing processes and identified areas where improvements were needed. This review highlighted the need for a more structured approach to integrating ESG principles into our R&D activities.

 

Setting Ambitious Goals

Our grand objective is to ensure that 100% of our projects are covered by environmental performance indicators. One of the first key performance indicators (KPIs) we adopted was Process Mass Intensity (PMI). Specific targets for PMI reduction were set within the IPCEI project, serving as a demonstrator of our commitment to minimizing environmental impact while maintaining high standards of innovation.

 

The PMI metric is particularly significant because it measures the efficiency of our processes in terms of material usage. By focusing on reducing PMI, we aim to minimize waste, decrease water and energy consumption and improve the sustainability of our operations. This goal is aligned with our broader commitment to reducing our environmental footprint and promoting sustainable practices across all aspects of our business.

Collaborative Efforts and Methodology Development

The IPCEI initiative spurred a collaborative effort involving our R&D, Industrial Operations, and ESG teams. Together, we established the necessary ways of working to integrate environmental indicators as key performance metrics across all company projects. Our approach incorporates key environmental indicators such as greenhouse gas emissions, energy consumption, circularity and waste management, water usage, and biodiversity into our performance criteria.

 

In terms of partnerships, we also initiated a CDMO collaboration with SpiroChem, a leading Contract Research Organization headquartered in Switzerland. This agreement enables us to provide customers with integrated customized solutions to make their chemical drug development shorter, greener and more cost-efficient. CDMO is collaborative by nature and collaboration has been a cornerstone of our ESG strategy. By bringing together experts from different disciplines, we have been able to develop a holistic approach to sustainability. This collaborative effort has also fostered a culture of innovation, as team members are encouraged to share ideas and work together to solve complex problems.

 

Implementation Strategy and Tools

To achieve our ambitious goals, we developed a comprehensive implementation strategy. This included defining the indicators, establishing processes to evaluate them, and creating user-friendly tools to facilitate their application. Several tools were evaluated and tested on several complex molecules in our portfolio. This methodology not only helps estimate the carbon footprint of our products but also provides high-quality visualizations.

 

Let’s take another concrete example: EUROAPI’s Research and Development teams have made significant strides in enhancing the sustainability of solid-phase peptide synthesis (SPPS). A study recently introduced a groundbreaking method that combines real-time monitoring using Raman spectroscopy, the use of a rotating bed reactor, and the substitution of traditional solvents with greener alternatives. This pioneering work published in Sustainable Chemistry & Engineering of the American Chemical Society by EUROAPI’s dedicated team not only advances the field of peptide synthesis but also sets a new standard for sustainability in the pharmaceutical industry.

 

Key Drivers and Results

Our efforts have yielded significant results. For example, in the field of tuberculosis treatment, EUROAPI’s rifampicin API has been improved. Thanks to the hard work of our R&D and industrial teams, we have been able to monitor and control all the parameters and can now provide our customers with a high-quality API that meets the new requirements for nitrosamine impurity standards.

 

By running reactions under more concentrated conditions, simplifying work-ups, and optimizing liquid-liquid extractions, we have achieved substantial reductions in PMI for several projects. These achievements demonstrate the effectiveness of our strategies and the potential for broader application within our projects. By improving the efficiency of our processes, we are able to reduce waste, lower costs, and enhance the overall sustainability of our operations.

 

Future Directions and Integration
Looking ahead, we aim to fully integrate these environmental indicators into our workflows. This includes defining roles and responsibilities, establishing training methods, and incorporating these objectives into employees’ performance metrics. By aligning objectives across departments, we ensure a cohesive and committed approach to achieving our ESG goals. We plan to continue fostering a culture of innovation and collaboration, encouraging our team members to think creatively and work together to achieve our sustainability goals.

 

In conclusion, our journey towards integrating ESG principles with innovation is a testament to our commitment to sustainable progress. By setting ambitious goals, fostering collaboration, and developing robust methodologies, we are transforming our company. As we continue to innovate, we remain dedicated to minimizing our environmental impact and contributing to a more sustainable future.

 

–

 

 

Adapting B2B Operations in Pharma: Embracing AI, ESG, and Enhanced GMP for Sustainable Innovation

 

Historical Focus and Outsourcing Success: Historically, B2B relationships in pharmaceuticals have revolved around optimizing processes to meet demands for quality and cost-effectiveness. This led to the successful outsourcing of fine chemical manufacturing to CMOs and CDMOs, enabling pharmaceutical companies to leverage specialized manufacturing capabilities while focusing on core competencies such as drug discovery.

 

Necessity of Shifts Due to ESG, AI, and Digitalization: With the advent of Environmental, Social, and Governance (ESG) standards, alongside advancements in Artificial Intelligence (AI) and digitalization, there is a pressing need for B2B companies to expand their operational focus. These modern demands require integrating sustainable practices and advanced digital tools, moving beyond traditional cost and efficiency optimizations.

Limitations of Individual B2B Investments: Single B2B entities, not only smaller firms, often lack the resources to invest effectively in AI and adapt to ESG criteria. Challenges include financial constraints and a shortage of specialized managerial skills needed for navigating these advanced technologies.

 

Resource Sharing and Industry Partnerships: Through resource sharing and industry partnerships, B2B companies could pool resources such as capital and technology. This collaboration would enabled access to AI applications and compliance with ESG standards, distributing the investment burden and reducing individual risks.

Pivotal Role of Big Pharmaceutical Companies: Big pharmaceutical companies are crucial in driving these industry-wide changes.
They can lead in investing in new technologies and advocating for updated Good Manufacturing Practices (GMP) that incorporate sustainability measures, ensuring that manufacturing processes benefit both patients and the planet. Their leadership in setting and advocating for these standards is vital for modernizing GMP to encompass environmental and social governance criteria.

 

Collective Data Pools: Collaborative data sharing among companies enhances the effectiveness of AI, providing large, diverse datasets that improve predictive analytics and decision-making processes in line with ESG goals.

Early Insights and Fluid Boundaries: The collaboration allows for insights from pilot projects, fostering an environment where companies can dynamically adapt to new findings and technological advancements. Fluid boundaries in these partnerships would facilitate knowledge and resource exchanges.

 

Extended Investments Across the Value Chain: Investments need to span the entire value chain, supporting joint ventures and shared platforms that test and refine sustainable practices in a cooperative setting. This helps in building a robust framework for continuous innovation and improvement.

 

Strategic and Change Management Support: Big pharma should also focus on enhancing strategic and change management capabilities within their supply chains. Providing training, resources, and support for these essential skills ensures that B2B partners can effectively implement and benefit from technological and regulatory changes.

 

Embracing One Health: In conclusion, as the pharmaceutical industry evolves, embracing a One Health approach — which recognizes the interconnection between people, animals, plants, and their shared environment — becomes increasingly important. This holistic view underscores the necessity of sustainable practices that protect overall health ecosystems. Big pharmaceutical companies, by driving changes in AI adoption, ESG compliance, and GMP standards, play a pivotal role in ensuring that the industry not only meets current challenges but also contributes positively to the global ecosystem.

 

By fostering strong partnerships and encouraging comprehensive investments in innovation, the pharmaceutical industry can achieve a sustainable future that aligns with the broader goals of One Health, benefiting all stakeholders involved.

 

–

 

 

AI: A Valuable Tool, but not the Sole Solution To Sustainable Supply Chains

 

In what ways do you foresee AI transforming future ESG practices across industries, and how should companies prepare for these advancements?

The potential for AI tools to improve sustainability and optimize supply chains in API manufacturing can be considered in two parts: 1) new route development and 2) improvement of current product manufacturing.

1. New route development can benefit from computer-aided retrosynthesis planning, but this should certainly not be relied upon. These tools are often skewed toward medicinal chemistry-type applications, which focus mostly on standard (often obvious to a synthetic chemist) cross-coupling strategies. For process chemistry/manufacturing applications, however, the real benefit of such software is in the suggestion of unusual disconnections. For example, construction of heterocycles with functional groups in place, rather than step-inefficient functional group introduction/conversion. This often encompasses older chemistries, which can be efficient without requiring precious metal catalysts or special technologies.
   One must also be wary of suggested reaction conditions for such transformations. As we know, the methods for organic synthesis (on both lab and production scale) have evolved substantially, and older manufacturing routes will often use conditions that are unacceptable in modern processes (e.g. dichloromethane or dimethyl formamide as reaction solvents). The key here is to critically analyse literature data and the reactions done by others – simply because there is a lot of historical data for “successful” reactions, the conditions should still be (often completely) redeveloped for our modern and sustainability-conscious world.
2. With regards to managing/improving the supply chain for existing products, the data pool is more limited, since it will generally consist of data only from this specific product, company, or combination of both. Related data sources (e.g. for similar products) may be useful, but again, should be considered with caution. The required pool of historical data must be available in a standardized format, which should encourage structured and detailed recording. Open-source tools and frameworks for such recording, including analysis of PMI, are available (e.g. Chempager). Beginning to create a manageable database as early as possible is vital.

What future regulations or industry standards do you anticipate will have the most significant impact on the adoption of AI in ESG practices?

Currently, regulatory restrictions are a significant challenge for manufacturing entities in incorporating new technologies and advanced sustainability solutions. Although there must be allowance and encouragement for new approaches, the regulatory authorities are rightfully wary of AI-based solutions. The first step must be for science and knowledge-driven control strategies to become commonplace. With all of the analytical tools now available, building a background of sound process understanding, with associated models, should be the standard approach taken for regulatory approval.

 

AI-based solutions could be seen as contradictory to this, since they are generally data-driven, without detailed understanding of the process itself. This should certainly not replace the scientific understanding-based approach in the near future. Of course, it can be advantageous to incorporate AI as a complementary tool in process model development, however, standard modelling approaches are currently suitable in the majority of cases.

 

What immediate steps can companies take to source and standardize ESG data for AI-driven supply chain initiatives, particularly in fragmented industries like fine and specialty chemicals?

There are significant challenges to ensuring that data can be effectively and properly used in AI applications. To retrospectively engineer workflows into the required data formats and standards requires huge changes and, in many cases, it can be more straightforward to entirely re-invent the workflows. In this situation, small, agile and newly-founded organisations hold a tremendous advantage. They should analyse the current state-of-the-art in open/accessible data collection and design their workflows accordingly, to be AI-compatible and future-proof.

 

Another major challenge is: which data format to use? As more chemical companies become interested in AI and big data applications, they begin to develop their own standards. Although these standards operate within the same basic principles (e.g. FAIR: findable, accessible, interoperable and reusable), there will always be substantial differences. In this sense, it is certainly more beneficial to take the approach of adopting an open standard that is already published (e.g. SURF), rather than re-inventing the wheel.

 

What role do industry partnerships play in helping smaller companies participate in AI-driven ESG pilot programs?

Smaller companies will certainly face challenges in lack of data availability, however this can increasingly be offset by growing publicly-available databases (e.g. the Open Reaction Database, ORD). Companies are increasingly contributing to such databases, but there remains a time commitment to correctly format the data.

Collaboration with larger companies to build data pools will undoubtedly be challenging, due to the sensitivity of data, especially in the pharmaceutical industry. In this sense, the often-criticised “black-box” nature of many AI systems can potentially be advantageous. This could allow well-established companies to share an AI model trained on their datasets, without worrying about the specific IP-sensitive elements within such a dataset.

 

What new skills and capabilities will employees need to effectively leverage AI for enhancing ESG initiatives within organizations?

The main required capability for employees to learn is simply openness to new ideas and creativity to come up with new solutions. The modern chemist must embrace other disciplines and learn to apply good ideas from outside of their own field.
Aside from the employees themselves, many organisations are somewhat paralysed by rigidity and old-fashioned workflows.

 

They must provide freedom for their employees and encourage development of new, potentially custom-built, solutions.

What are the potential risks of relying on AI to meet ESG goals, and how can companies mitigate them?

As with all applications of AI methods, the users must critically analyse the outputs/suggestions. In many cases, AI is not the most suitable tool for the job. When large amounts of data are available, a human operator can often use data visualisation tools to come to a sound conclusion, which may be better rationalisable than an AI-generated decision. AI should not be used as a blanket tool to replace sound and well-reasoned decisions by experienced scientists.

 

–

 

 

AI and ESG Integration: A Blueprint for Sustainable and Responsible Business Practices

AI and ESG (Environmental, Social, and Governance) are converging to redefine how businesses approach sustainability, ethics, and operational efficiency. AI’s ability to analyze and predict outcomes from vast datasets is transforming industries, particularly sectors like healthcare and pharmaceuticals that are reliant on complex supply chains. Its integration into ESG initiatives may help enhance transparency, optimize resource usage, and ensure compliance with environmental and ethical standards, fostering a more sustainable and equitable future.

 

Optimizing Sustainability in Supply Chains

Soon, AI may play a critical role in reshaping global supply chains by streamlining operations, minimizing waste, and driving sustainability. In healthcare and pharmaceuticals, for instance, AI algorithms can be used to scan extensive data to accurately predict drug demand, guiding companies in optimizing inventory levels, drug production schedules, and transportation plans.

 

With AI’s ability to forecast demand fluctuations, the healthcare sector can anticipate risks and adapt supply chains to real-time changes. This capability is essential in managing disruptions caused by events such as global pandemics (as was evident with COVID-19), natural disasters, geopolitical conflicts, or even regulatory shifts. AI-driven predictive models allow companies to proactively design contingency plans, maintain steady supply flows, and allocate resources efficiently, ensuring resilience even in uncertain times.

 

This approach will, in turn, promote energy conservation and support waste reduction, leading to integrating circular economy principles. As such, AI advancements not only optimize supply chains but also strengthen alignment with ESG objectives.

 

Promoting Transparency and Ethical Sourcing

Transparency and traceability are foundational to ESG practices, and AI is a game-changer in this regard. Advanced AI-driven traceability systems can monitor the journey of products from their source to the consumer, ensuring that every step aligns with ethical and sustainable standards. By analyzing anomalies and identifying potential risks, these systems enable companies to rectify issues and maintain the integrity of their supply chains.

 

AI’s reach can also extend to monitoring labor conditions and compliance with fair labor standards. By analyzing data from diverse sources —i.e. social media, news, and worker surveys— AI identifies patterns of labor violations, flags potential abuses, and alerts organizations to intervene. This capability ensures companies adhere to ethical labor practices while promoting accountability.

 

Additionally, AI improves the accuracy and efficiency of ESG reporting. Automating data collection and analysis reduces human error, ensures reliability, and builds stakeholder trust. This level of transparency enhances overall ESG performance, enabling organizations to meet their goals and commitments effectively.

Building Resilience and Agility in Supply Chains

AI technologies, including machine learning, predictive analytics, and digital twins can significantly boost supply chain agility and resilience. Digital twins simulate real-world supply chain scenarios, allowing businesses to test strategies and identify potential bottlenecks. The Internet of Things (IoT) along with modern Laboratory Information Management Systems (LIMS) powered by AI can provide real-time data on inventory levels, equipment health, and transportation conditions, enabling swift responses to unexpected challenges.

 

AI also supports long-term resilience by optimizing routes, improving logistics, and minimizing disruptions. For example, AI-enabled models can predict risks like material shortages or regulatory changes, allowing companies to diversify suppliers or stock inventory strategically. This capability ensures businesses remain agile in the face of shifting global dynamics and safeguard operational continuity.

 

Closing Data Gaps to Meet ESG Goals

Data is the backbone of effective ESG integration. However, many organizations face significant gaps in their data management processes, with fragmented data across many disparate sources. AI-enabled data management technologies like LIMS and SDMS (scientific data management system) can address these challenges by automating the collection, cleaning, and standardization of data. Establishing a robust data management strategy is the key to generating reliable and meaningful AI insights. These insights can enable companies to make informed decisions towards achieving ESG goals.

 

A comprehensive data audit can reveal missing elements, helping organizations prioritize critical data points and align them with their ESG goals. To address fragmented data landscapes, businesses can leverage existing sources such as internal reports, supplier questionnaires, and third-party ESG data providers. Standardized templates and centralized data repositories ensure consistency, accuracy, and accessibility. Companies should also adopt tools that integrate and clean data from various origins to enhance reliability and usability.

 

Collaboration with industry peers and standards agencies further helps address these challenges. By participating in forums and working groups, businesses can influence the development of industry-specific ESG standards, share best practices, and improve data-sharing frameworks.

 

Immediate Steps for AI-Driven ESG Integration

To harness AI’s full potential in advancing ESG initiatives, organizations can take several practical steps:

Define Key ESG Metrics: Identify and prioritize metrics most relevant to your industry and align them with established frameworks like GRI or SASB.

Leverage Existing Data: Use internal financial, operational, and sustainability reports; engage suppliers through surveys or direct communication; and explore reputable third-party ESG data providers.
Standardize Data Practices: Create templates for consistent data collection, implement quality checks, and adopt centralized repositories for seamless data management.
Adopt Data Management Tools and AI Pilots: Use a centralized platform to store and manage ESG data and employ tools to clean, standardize, and integrate data from various sources. Launch focused initiatives such as predictive AI analytics for supply chain disruptions or energy optimization, using a pilot-and-learn approach.
Collaborate Across the Industry: Participate in industry forums to exchange knowledge, advocate for ESG standardization, and influence best practices.

Iterate and Improve: Continuously refine AI/ML tools, data practices, and strategies based on evolving business needs and regulatory landscapes.

 

The integration of AI into ESG frameworks is paving the way for a transformative future. AI not only optimizes supply chain operations but also fosters a culture of accountability, transparency, and sustainability. By automating processes, predicting risks, and improving resource allocation, AI empowers businesses to address climate challenges, promote ethical practices, and achieve their ESG objectives. The road ahead requires a concerted effort to bridge data gaps and enhance collaboration. With a proactive approach, organizations can fully unlock the potential of AI to drive meaningful change and build a greener, more equitable world.

 

–

 

 

What future regulations or industry standards do you anticipate will have the most significant impact on the adoption of AI in ESG practices?

MTP will become an important industry standard for the automation of process equipment. This enables the connection between plants, modules, infrastructure and other equipment independent of the equipment or automation vendor using a universal protocol. This enables a fast and flexible production of chemical and pharmaceutical products. The MTP standard can be compared with the well-known USB standard at computers. The peace of equipment is plugged into the central control system call POL (process orchestration layer). The process can be orchestrated out of services provided by each piece of equipment. Communication between different parts of the equipment will be the base for AI.

 

What are the potential risks of relying on AI to meet ESG goals, and how can companies mitigate them?

AI is a very energy-intensive technology. AI has become a big hype generating a huge demand of resources and it is exponential growing. The question is, if resources in terms of computing and server-farms including its energy demand can be provided fast enough. If not, would there be a selection of AI applications, which are served by limited resources and others not? Will businesses become dependent on the availability of AI and how could they cope with an AI shortage caused by a resource shortage? Companies should develop strategies to deal with AI shortages.

 

How do you foresee AI enabling a more circular economy in supply chains by supporting ESG initiatives like waste reduction and resource optimization?

I expect a push towards better chemical processes, The development of these processes will be AI supported. Better process lead to less work-up und less waste. AI will support by partly autonomous experimentation as well as in the suggestion for better starting points. Technology selection will be AI supported. Better processes generate a cost advantage. New chemical transformations will be used, since flow chemistry can enable these. This will open strategies impossible in batch, where a significant impact on waste reduction is expected.

 

Can companies leverage AI to transform their business models, and if so, how?

Speed will become the dominant business driver for a business models not only quality and costs. That opens new strategies. The pharma company might not own technology or plants in the future. They might rent technologies and equipment to be on the market as quick as possible to be the first that covers a certain demand. Modularity and flexible automation for example by MTP will be a key for speed. Not the best solution will win, the fastest solution for covering the demand will win. AI will reduce development times significantly for a quicker time to market. Telecoping can reduce manufacturing times dramatically. That means connecting synthesis steps without intermediate work-up. They can sometimes be financed by a reduction in working capital.

 

What immediate steps can companies take to source and standardize ESG data for AI-driven supply chain initiatives, particularly in fragmented industries like fine and specialty chemicals?

Measuring data and storing of process data will be the base for further activities. In the past a lot of processes have been developed and never touched again. The core competence is process knowledge for the process industries and it grows with a focus on data. The more data are available about their processes, the better AI can support and give suggestions for improvement. This means that data management and data analysis become important. Learnings about the process and the usage for improvement will be a key factor for an improved competitiveness in the future.

 

–

 

 

What are the key challenges industries face in embedding ESG principles into their global supply chain strategies?

A global supply chain strategy needs to feed into the organisation’s business goals; hence, a stated business goal on ESG adoption must be a pre-requisite. The first challenge is the sheer complexity of sustainability initiatives, from product/process development to disposal (reduce/reuse/recycle), which calls for technical, safety and commercial ability. The lack of a single global mandate comes in the way of chalking out an international strategy. While industry-level emphasis differs, multiple reporting initiatives with varying emphasis is another challenge. The shift to a greener choice involves added costs in the short-term; lack of incentives (govt/industry) means lack of competitiveness, which can be counter-productive to business goals. With the looming uncertainty at a global level, longer-term initiatives such as sustainability are hard to justify. Supply chain efficiency involves picking the right source for the requirement and factoring sustainable metrics to drive sourcing decisions, which is what is called for and implemented.

Can companies leverage ESG regulations to transform their business models, and if so, how?

If viewed in the proper perspective, ESG goals can be truly transformative in the pharmaceutical industry – green chemistry, enzymatic transformation, flow chemistry, waste heat recovery and finding re-use for the byproducts are at the core of sustainability pathways. While involving upfront capital investment and effort, these have proven to be game changers in many high-volume products. Hence, if ESG goals are well directed, keeping in mind the strategy that will suit the organization, products and processes, it can be truly transformative and disruptive, delivering a significant competitive advantage. In addition, in people and governance, ESG regulations encourage the organisation to adopt a progressive, altruistic and transparent culture and practice that ensues in self-regulation and fosters long-term sustainability.

 

What roles do collaborations and partnerships play in driving sustainability across the biopharma value chain, especially in reducing Scope 3 emissions?
Context: The role of the government is to drive the choice of sourcing partners based on geopolitical issues.

Scope 3 concerns the emissions from the operations of stakeholders downstream and upstream that are not directly controlled or owned by the organisation. A reduction in Scope 3 carbon footprint calls for the organisation to engage, handhold, aid in gap assessment, co-find action areas and influence the implementation of those actions. Influence directly stems from business leverage and/or shared vision on sustainability. Since the solution involves increased transparency, culture change, committing investments and related costs, a shared vision of the future and building mutual trust is called for. Collaboration and partnerships are at the core of addressing scope-3 emissions.
 
In what ways do you foresee AI transforming future ESG practices across industries, and how should companies prepare for these advancements?

It is indisputable that advancements in science, technology and medicine have improved life expectancy and dignity and reduced overall scarcity . However, this has come at a significant cost to the environment and threatens the planet’s long-term sustainability. The challenge before countries, governments and corporations is to make the planet greener and cleaner without losing the advantages of modern economic thought and activity. The solution lies in innovation, sustaining breakthroughs (such as hydrogen fuel cells for cars, green buildings, green chemistry in all chemical processes, miniaturization, etc.) that place reduced emphasis on exploiting natural resources and deforestation. AI has a significant role to play in this discovery process. AI has already proven a unique capability to quickly assimilate past research and use algorithms to develop probable choices from vast simulations. These choices can then be taken up for research and experimentation, potentially reducing the need for increased experimentation and investments. AI should be harnessed to target areas of significant ESG risks such as fermentation technology, dangerous reactions, recoveries and economical use of waste generated in large quantities.

 

How do you foresee AI enabling a more circular economy in supply chains by supporting ESG initiatives like waste reduction and resource optimization?

If there is a solution that delivers results at a quantum level for achieving ESG objectives, it lies in achieving a classic circular economy! Examples from Japan – Kitakyushu, Shirakawa, and Tarkett from Europe- are models of adopting circular economy principles – while not giving up on modern economic progress. Scale up these models or explore other models to create a circular economy. A vast amount of industrial waste and by-product data must be processed, and combinations must be intelligently combined to find applications for these as inputs into other industries. This needs to be researched and worked upon to explore making these ‘fit to use’ in those industries, which is the key challenge. I believe AI has the exact capabilities to collect, classify, and work on permutations and combinations to develop innumerable possibilities and enable applications. Process optimizations by screening options from the world of science that led to input reduction and targeted waste reduction by minimizing generation from the process are other essential activities that need enormous computing and simulating power with intelligence. AI comes in handy here.

 

–

 

 

What are the key challenges industries face in embedding ESG principles into their global supply chain strategies?

The COVID-19 pandemic undeniably marked the start of a new era of “polycrisis,” characterized by continuous, frequent and devastating crises. As leading API supplier, with HQs in Italy and a global manufacturing network comprising 11 production sites and 7 research centers worldwide, we have been facing this challenging moment trying to transform crises into opportunities and making its complex operational model resilient and flexible. One of the key factors to be successful is sustainability.

 

We have firmly set out on a sustainability journey and 2023 was marked by great strides toward energy transition, significant investment in systems that harness alternative energy sources, and social and economic involvement and support for the communities in which we operate. We reaffirmed our commitment to creating an increasingly sustainable and certified supply and production chain by transferring our values and standards to our global suppliers, and we continued our efforts to develop innovative production processes with an ever-decreasing environmental impact through research and development projects.

Olon social responsibility road map will help us to strengthen the implementation of the United Nations Global Compact initiative guidelines — a voluntary leadership platform for the development, implementation and disclosure of responsible business practices throughout the value chain. We are very proud to disclose that we’ve officially joined the UN Global Compact Initiative. Progressing towards even more ambitious sustainability goals
Energy efficiency measures lead us towards carbon neutrality in our own operations. Against the backdrop of the early achievement of the 2018 / 2025 targets, the group has set itself new long-term environmental targets; these represent a highly challenging and ambitious goals to minimize our environmental impact according to Company ESG strategy.

 

What role do consumers and stakeholders play in driving ESG compliance in global supply chains, and how should companies respond?

Olon believes in the utmost importance of building strong relationships and connections with its stakeholders. Indeed, it is through their engagement and involvement in business activities that the Organization can better assess its impacts and monitor the way it operates, by becoming aware of their needs and expectations.
The stakeholder engagement process starts with the identification of the relevant stakeholders and of the means that can be used to reach them. Olon invests constantly and daily in building these relationships, to get the valuable exchange of opinions and points of view that help meet the needs of all the stakeholders.

 

What are some successful case studies of implementing green chemistry and eco-design?

Olon strives to continually drive innovation in advanced science, while creating long-term value for all stakeholders, through sustainable industrial and technological solutions. Innovation is embedded in Olon’s business model, enabling the Company to be more agile on sharpening the focus on core business and optimizing the phases of research, while maintaining high standards of product quality and safety, ensuring product accessibility to a wide range of people and reducing their environmental footprint. Olon is working on cutting-edge R&D processes applied both to chemistry, in terms of flow chemistry, photochemistry, and electrochemistry, and to biotechnologies. Investing in and developing technological advances allows the Organization to combine well-established practices with new ones, to guarantee efficient and successful manufacturing processes, at the same time ensuring safe, fast and cost-effective commercial processes.

 

This innovative production technique enables a double positive impact in terms of sustainability. Indeed, it allows for the use of small era amounts of material per unit time, therefore resulting in increased local temperature control and in the possibility to avoid extreme temperatures, making the manufacturing process less energy intensive. It also provides greater safety for operators and along with the process itself, due to the possibility of using limited quantities of products that react together at any given time.

In addition to that, the latest technological advances will make it possible to use light, through photochemistry, or electricity, through electrochemistry, to power reactors, which would otherwise be unfeasible under the conventional conditions of a higher need for chemical reagents and extreme temperatures.
The industry is now facing a paradigm shift, in which there is a continuous exchange of knowledge and information between the chemical and engineering sectors, which eventually results in the creation of new specific know-how and business synergies.

 

Today the urgency for more cost-effective, robust and selective chemical transformations is increasing. Biocatalysis meets these requirements. Biocatalysis refers to the use of biological systems or their parts to catalyze a reaction: it means the reaction mechanism allowed by the biocatalyst (e.g. enzyme) makes the reaction possible either in absolute sense or in milder conditions if compared to corresponding chemical reaction. More and more biocatalyzed reactions have been extensively studied and are currenly under investigation.
Aware of the enormous potential of biocatalysis, in October 2021 Olon took a further step towards the “build” approach and announced the creation of an international network of scientific excellence thanks to a partnership with Biosphere — an Italian SME specialized in fermentation and industrial biotechnology —, University of Turin, University of Milan, and the Biocatalysis Group of the Van’t Hoff Institute for Molecular Sciences (HIMS-Biocat) at the University of Amsterdam (UvA). These strategic partnerships aim at the identification of most effective enzymes for selected types of reaction, before scaling up the production of the biocatalyst and the bioconversion process to industrial levels.
Olon is currently involved in three main projects, that have different goals and that are currently at different stages. Olon and the University of Milan’s Department of Chemistry created a Scholarship for a PhD in the development of new photochemistry-based processes applied to the production of active pharmaceutical ingredients. The goal of the project is to develop new alternative routes of synthesis based on photochemistry; a highly innovative, sustainable process that can be systematically applied to industrial-scale production. Olon’s co-funding enables a PhD student from the University of Milan to work for three years on cutting-edge research topics, at the end of the course leading to the development of alternative processes for concrete industrial application at Olon sites.
The Department of Chemistry also has great expertise in flow chemistry, complementary to the area of photocatalysis.

Olon is working in collaboration with the University of Milan’s Department of Chemistry by mean of a Scholarship for a PhD student, started in 2022, and, in early 2024, an additional one-year scholarship for a research fellow.
The aim of the project is the development of new alternative routes for the synthesis of APIs based on photochemistry. In particular, the focus of the work is the development of metal-free photoredox synthesis of anilines (formation of Ar-N bond), and more recently also metal-free photoredox Ar-Ar coupling.
The objective is to develop efficient and sustainable processes, through the application of new technologies. For the introduction of an amino group onto an aromatic ring, the main reactions currently used, especially on an industrial scale, suffer from drastic reaction conditions (for example nitration reactions followed by reduction), the use of dangerous reagents, as well as poor atom-economy, resulting in the production of large quantities of waste. On the other hand, cross-coupling reactions are one of the most common classes of chemical transformations: the general approach requires the use of expensive and rare metals such as Copper, Nickel, or, more commonly, Palladium. Furthermore, the preparation of the coupling partners requires multiple synthetic steps, often involving low temperature reactions, and the use of protecting groups, due to the low compatibility with numerous functional groups, commonly present in API scaffolds.
Currently, more than 20 APIs among the active processes in Olon contain an aniline moiety, and more than 10 an Ar-Ar moiety: six targets (three for the Ar-N, three for the Ar-Ar coupling) were selected for preliminary studies of feasibility conducted at the University.

 

The first phase of the project was the selection of the best synthetic route for the targets, in order to include the photoredox catalytic reaction, focusing also on atom economy and sustainability. At the same time, a library of known organo-based photocatalysts was prepared, and the photoredox catalytic reactions for Ar-N formation and Ar-Ar coupling were tested on model substrates.

 

–

 

 

AI-Driven ESG Excellence in CDMO Companies

 

What are the primary challenges companies face when adopting AI to meet ESG goals?

The chemical industry’s journey towards sustainability is often impeded by the initial hurdle of data scarcity. In the CDMO sector, AI integration is contingent upon the digitization of processes, which is pivotal for creating digital assets—crucial for AI and automation to enhance ESG practices. The industry is evolving towards agile manufacturing models that embrace advanced technologies, such as continuous manufacturing. However, without a robust foundation of digital assets, these advancements are unattainable. For companies to integrate AI into their daily operations and meet ESG goals, the first step is to accumulate digital assets. At PharmaBlock, for instance, we’ve established a chemical process safety database, centralizing all process safety data from our chemists’ tests. This system not only facilitates easy access to safety information but also allows us to accumulate data, which is essential for future machine learning applications that predict chemical process safety. As we continue to gather more data, we’re laying the groundwork for AI to play a more predictive role in our operations.

 

What role do collaborations and partnerships play in driving sustainability across the biopharma value chain, especially in reducing Scope 3 emissions?

Collaborations and partnerships are the lifeblood of sustainability in the biopharma industry, particularly when it comes to managing Scope 3 emissions. At PharmaBlock, our ESG commitments are initially client-driven, with a focus on carbon footprint calculations and reductions. Pharmaceutical companies consider the carbon footprint of CDMO partners as part of their Scope 3 emissions, making it our responsibility to develop a methodology for carbon footprint calculations. Given the diversity of chemicals and production processes across numerous client projects, accurate allocation is a complex task. We’ve initiated carbon footprint reporting for client projects and are developing our carbon footprint calculation methods. By integrating global and industry-standard emission factors, we’re building data models to expedite project carbon footprint calculations through daily operational data collection. Moreover, to address the challenge of Scope 3 data collection, we’re aligning with our suppliers. We’re educating and training our key suppliers and plan to use digitalization to assist them in carbon footprint data collection, thereby enhancing the sustainability of our supply chain. We believe that sustainability is a collective effort that cascades up the supply chain, with each layer taking responsibility for controlling direct and indirect emissions and aiding suppliers in managing theirs.

 

What are some successful case studies of implementing green chemistry?

Beyond operational excellence, green chemistry and engineering are pivotal in significantly reducing carbon footprints. At PharmaBlock, we’ve harnessed the power of low-carbon technologies across thousands of projects, exemplified by continuous flow manufacturing. Our integration of Distributed Control Systems (DCS) with continuous flow manufacturing is creating a synergy that enhances efficiency and sustainability, by monitoring and managing various processes, facilitating data acquisition from sensors and actuators. The convergence of DCS with AI is a burgeoning trend that explores future automation potentials. AI-DCS integration opens up new possibilities for enhanced process control, predictive maintenance, real-time optimization, and operational excellence. Additionally, generative AI is aiding companies in accessing and accumulating Green Chemistry knowledge. For example, PharmaBlock has established an AI knowledge platform for enzyme catalysis, streamlining the screening and selection of enzymes.

How can organizations use AI to train and upskill employees on sustainable practices and ESG compliance?

At PharmaBlock, we recognize the importance of effective AI training, intellectual property management, and ethical education in leveraging AI responsibly. We offer internal AI training programs to familiarize our employees with AI, ensuring they are prepared for the future. We prioritize the ethical use of AI. To safeguard IP, we’ve been constructing our own AI server and tools.

 

AI also contributes to employee care by fostering a safer and more efficient work environment. For example, at PharmaBlock our intelligent warehouse system minimizes manual errors and health risks associated with direct chemical exposure, enhancing safety and operational efficiency.

 

Can companies leverage ESG regulations to transform their business models, and if so, how?

ESG is a comprehensive framework that encompasses various aspects of a company’s operations, including the environment, human resources, and sustainable supply chains etc. Leveraging ESG regulations can indeed be a catalyst for business model transformation. ESG regulations encourage companies to adopt sustainable practices, reduce environmental impact, and disclose climate-related risks and opportunities. This leads to the adoption of cleaner technologies, energy efficiency improvements, and waste reduction initiatives, which not only lower carbon footprints but also result in cost savings and operational efficiencies. At PharmaBlock, the adoption of ESG regulations has led to healthier business operations. We view ESG not as a mere compliance exercise but as a guide for responsible business practices towards employees, communities, customers, and the industry. This sense of responsibility fosters healthier business development. Through systematic management, we’ve achieved a silver medal score for our headquarters and bronze medals score for our production base in EcoVadis this year, reflecting our commitment to ESG.

 

–

 

 

What are the primary challenges companies face when adopting AI to meet ESG goals, particularly in relation to carbon reduction, ethical sourcing, and transparency?

ESG goals such as carbon reduction, ethical sourcing, and transparency present challenges related to data, technology, cost, governance, and stakeholder alignment that must be addressed at a strategic level. Integrating AI into legacy systems, managing algorithm complexity, and ensuring scalability add technical barriers; high implementation costs and ongoing maintenance pose financial constraints.

 

Ethical concerns, such as biases in AI models and transparency in decision-making, complicate accountability, especially amid evolving global ESG regulations. As with all digital transformations, an organization must address cultural resistance and the need to align diverse stakeholder expectations.

In what ways do you foresee AI transforming future ESG practices across industries, and how should companies prepare for these advancements?

AI is set to transform ESG practices across industries through data management, enhancing predictive capabilities, optimizing supply chains, improving process efficiency, and advancing ESG reporting and transparency. In biologics manufacturing, AI can significantly reduce water consumption and waste in downstream processing through the application of machine learning algorithms that continuously analyze and adjust process parameters in chromatography, filtration, and other downstream steps. AI can lead to more efficient use of water and consumables.

 

To prepare, companies should invest in robust data infrastructure. AI applications depend on the integrity and quality of the data being analyzed for modeling. Developing AI strategies that align with ESG goals is an important step. Companies can enhance their ESG performance, improve operational efficiency, and position themselves as leaders in sustainable business practices by embracing AI. AI-ESG synergy can drive long-term sustainability and optimize supply chains across industries.

 

What are the most promising AI technologies for enhancing supply chain resilience and agility?

Predictive analytics, real-time monitoring, automation, digital twins, and proactive risk mitigation are the most promising AI technologies for enhancing supply chain resilience and agility. Predictive analytics improves demand forecasting accuracy and enables risk management by analyzing historical data and market trends and fluctuations. Coupled with real-time monitoring, AI driven supply chains can anticipate and adapt to potential disruptions. Generative AI is applied in the area of risk response through scenario and safety simulations. Collectively, these technologies enhance visibility and predictability, for flexibility in strategic decision-making across the supply chain network.

 

How can AI be used to predict and mitigate supply chain disruptions, such as those caused by global events or regulatory changes?

Pharma is using AI coupled with specific analytical approaches to anticipate and mitigate supply chain disruptions and enhance supply chain resilience. By analyzing historical and real-time data it is possible to not only optimize current supply chain processes and operations but react to real-time threats from geo-political, regulatory, epidemiology and weather-related disruptions. Scenario analysis allows contingency planning while alerting managers to early signs of disruptions like political instability. Recommendation systems suggest alternative suppliers or routes when disruptions occur, minimizing impact and informing decision making.

 

Can companies leverage ESG regulations to transform their business models, and if so, how?

Companies can strategically integrate sustainability initiatives into their core operations, using AI, data management and IoT to enhance efficiency and reduce emissions. By aligning ESG goals with growth, they can create a competitive approach that allows them to tap into new markets. ESG compliance is a catalyst for innovation in products and processes that fosters stakeholder engagement and enhances brand reputation. Focusing on ESG factors, companies can reduce costs, increase revenues, and create long-term value. To capitalize on these opportunities, businesses should develop robust ESG management capabilities, align non-financial KPIs with financial metrics, and proactively engage with regulatory changes. This strategic approach turns regulatory challenges into opportunities for sustainable growth and business model innovation.

 

–

 

 

What are the primary challenges companies face when adopting AI to meet ESG goals, particularly in relation to carbon reduction, ethical sourcing, and transparency?

First, implementing AI solutions can be expensive, requiring significant costs for system maintenance, updates and personnel training, which may be hard to evaluate returns in the short term. This is not only about the investment of the company itself, but also the supply chain’s investment. It’s not about one supplier, but maybe hundreds and thousands of them. Besides, AI systems rely on vast amounts of high-quality data. It is always hard for companies to collect accurate, consistent and comprehensive data, like the data related to carbon emissions and supply chain. Integrating new AI systems with existing data infrastructures can also be complex and costly, requiring significant changes to legacy systems. Meanwhile, accurately modeling and predicting carbon emissions involves complex algorithms and datasets that must consider numerous variables and dynamic factors within supply chains and operations. There is often a lack of in-house expertise to develop and manage AI tools that can effectively analyze and optimize carbon reduction strategies. Moreover, stakeholders such as suppliers may have concerns about the opacity of AI algorithms, especially if they are not transparent or understandable to non-technical users, leading to challenges in trust and acceptance.

 

How can AI help address regulatory challenges surrounding ESG compliance, especially with evolving frameworks like GRI, SASB, and CSRD?

Firstly, AI can continuously monitor for new regulatory changes and promptly alert companies to any updates or new compliance requirements. AI can help companies quickly adapt to new frameworks and requirements by adjusting metrics and disclosures accordingly in ESG reporting. Secondly, AI can help parse and interpret lengthy ESG regulations, standards, and guidelines, summarizing key requirements and identifying relevant sections for compliance. Thirdly, AI can automate the collection of ESG data from various sources, including internal systems, social media, and third-party databases, reducing manual effort and minimizing errors. AI tools can also consolidate and normalize diverse data sets to ensure consistency and comparability across different reporting frameworks. Companies can use AI-powered dashboards to customized visual represent ESG data and highlight key metrics and trends which can be tailored according to the evolving requirements of frameworks like GRI, SASB, and CSRD. Finally, through advanced analytics, AI can identify potential ESG risks and impact areas by analyzing historical data and predicting future trends. It can model various scenarios to assess the potential impact of different regulatory changes on ESG performance and compliance.

 

What new skills and capabilities will employees need to effectively leverage AI for enhancing ESG initiatives within organizations?

To effectively leverage AI for enhancing ESG initiatives within organizations, employees will need to develop a combination of non-technical and technical skills. For technical skills, employees need basic date literacy to interact with AI tools effectively. This includes understanding how to effectively analyze the data, interpret AI-generated insights and integrate these findings into ESG strategies. For non-technical skills, employees need to have the ability of critical thinking and problem solving, being able to analyze complex ESG data and scenarios to make informed decisions. They need to be creative and innovative cause leveraging AI technology always requires thinking outside the box to develop and implement novel solutions for ESG challenges. They need to have adaptability and learning agility. With AI technologies constantly evolving, employees need to continuously learn and adapt to new tools and methodologies. Most importantly, understanding the ethical implications of AI applications is crucial to ensure ESG initiatives align with organizational values and societal expectations. Thus, employees must have ethical awareness. These skills combined will enable employees to harness AI-driven solutions to streamline ESG reporting, improve decision-making, and predict future trends, ultimately enhancing an organization’s ESG performance.

 

How can organizations use AI to train and upskill employees on sustainable practices and ESG compliance?

Organizations can leverage AI in various ways to train and upskill employees on sustainable practices and ESG. AI can analyze individual employee profiles to identify knowledge gaps and learning preferences, then recommend personalized learning paths for understanding sustainable practices and ESG compliance, which ensures efficient and targeted learning. Additionally, AI can track progress in real-time and provide immediate feedback, helping employees grasp complex ESG topics more quickly. AI-driven analysis can evaluate employees’ understanding and retention of material, adapting future content accordingly. Furthermore, AI-powered platforms can facilitate knowledge sharing and collaborative learning among employees, where they can discuss and solve ESG-related issues together, enhancing collective understanding and commitment to sustainable practices. Finally, AI can be used to analyze large datasets on training outcomes, helping organizations understand which sustainability and ESG topics are well understood and which need more focus. This supports continuous improvement of training methods. AI can also help in predicting future skills required for ESG and sustainability initiatives, allowing organizations to proactively train employees for upcoming challenges and compliance requirements. By integrating AI into training programs, organizations can ensure that their employees are not only knowledgeable about sustainability and ESG compliance but are also actively engaged and capable of applying this knowledge in their work.

 

–

 

 

What are the emerging trends in the integration of AI and ESG in global supply chains, particularly in industries like healthcare and pharmaceuticals?

Emerging technologies, particularly AI, are transforming global supply chains in the pharmaceutical sector. AI-driven data analytics enables companies to enhance visibility, transparency, and efficiency across their supply networks. By integrating AI, companies are achieving real-time tracking of product flows, which aids in reducing waste and ensuring compliance with ethical sourcing practices. Moreover, aligning AI with Environmental, Social, and Governance (ESG) goals has become a growing priority, enabling pharmaceutical companies to monitor carbon footprints, energy use, and waste reduction efforts more effectively. For instance, generative AI applications in manufacturing workflows are helping streamline complex operations and reduce material usage, minimizing the environmental impact of production activities. Many organizations are embracing these changes, following trends seen in sectors like life sciences and healthcare, where AI enhances resilience, operational readiness, and sustainability initiatives

 

What are the primary challenges companies face when adopting AI to meet ESG goals, particularly in relation to carbon reduction, ethical sourcing, and transparency?

While the integration of AI for ESG initiatives offers promising benefits, companies face significant challenges. Key obstacles include high implementation costs, the complexity of scaling AI solutions, and the need for well-defined ESG metrics across regions. For example, carbon reduction requires standardized data measurement and interpretation, which is challenging in a globalized and often fragmented supply chain. Furthermore, ensuring ethical sourcing practices means accessing transparent supplier data, which is complicated when suppliers are spread across different jurisdictions with varying regulations. To overcome these hurdles, companies are investing in ecosystem partnerships that enhance data interoperability and foster a unified ESG reporting framework. Additionally, cross-functional expertise and analytical modeling skills are essential to maximize collaboration, yet these capabilities often require substantial upskilling efforts for employees​.

 

How can AI help address regulatory challenges surrounding ESG compliance, especially with evolving frameworks like GRI, SASB, and CSRD?

As ESG regulations continue to evolve, frameworks like the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB), and the Corporate Sustainability Reporting Directive (CSRD) impose complex compliance requirements on companies. AI can play a critical role in simplifying ESG compliance by automating data collection and analysis for timely reporting. For example, AI-driven systems are capable of processing massive data sets from various sources, identifying relevant ESG metrics, and detecting compliance anomalies, thereby reducing the likelihood of regulatory breaches. Automated solutions also help pharmaceutical companies manage documentation and produce ESG reports that align with multiple regulatory standards, ensuring adaptability as new frameworks emerge.

 

In what ways do you foresee AI transforming future ESG practices across industries, and how should companies prepare for these advancements?

Looking ahead, AI has the potential to further transform ESG practices by enabling greater resource efficiency and waste reduction. For instance, in the downstream processing of biologics—where water and consumables are extensively used—AI could improve process efficiency by analyzing usage patterns and recommending optimizations. This approach not only enhances sustainability but also boosts cost-effectiveness. Additionally, predictive AI models are expected to enhance long-term planning by forecasting supply chain disruptions and helping companies build resilient operations that align with their ESG objectives. Preparing for these advancements requires companies to invest in data-driven decision-making frameworks and in workforce training for better adoption of AI tools.

What new skills and capabilities will employees need to effectively leverage AI for enhancing ESG initiatives within organizations?

As AI becomes more integral to ESG initiatives, the pharmaceutical workforce must adapt by developing new skills. Employees will need competencies in data analysis, ethical sourcing, and sustainability management to interpret AI-driven insights effectively. AI platforms can also provide real-time ESG metrics, offering workers immediate feedback on their ESG performance and raising awareness of sustainable practices. Upskilling in analytical and cross-functional collaboration skills is crucial for employees to manage and interpret AI applications effectively. In addition, companies should foster partnerships with technology providers and academic experts to access the latest developments in AI and ensure that the workforce is prepared for future advancements​.

 

This comprehensive approach underscores the pivotal role of AI in meeting ESG objectives and the growing need for companies to cultivate adaptability and technological expertise to remain competitive in an increasingly data-driven, sustainability-focused market.

 

References and notes

Supply chain trends 2024: The digital shake-up
2024 Global Life Sciences Sector Outlook | Deloitte Global